The unique immunomodulatory properties of hydroxychloroquine (HCQ) have attracted considerable interest beyond its use for malaria and rheumatological diseases, including a variety of dermatological conditions. Over recent years, especially after the coronavirus disease 2019 (COVID-19) pandemic, the prescription of HCQ has also significantly expanded, sometimes inappropriately, thus posing additional challenges on its optimal use, due to emerging safety issues. In this review, we provide dermatologists with the latest advancements on selected clinically relevant toxicities, namely retinopathy, pro-arrhythmia, cutaneous reactions, and neuropsychiatric effects. It is hoped this update can assist dermatologists to identify high-risk patients for tailored monitoring, screening, and risk minimization strategies, thus supporting safer HCQ prescribing.

Rapparini, L., Cedirian, S., La Placa, M., Piraccini, B.M., Raschi, E., Starace, M. (2025). Safety of Hydroxychloroquine: What a Dermatologist Should Know. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 26(2), 251-264 [10.1007/s40257-025-00919-x].

Safety of Hydroxychloroquine: What a Dermatologist Should Know

Rapparini, Luca;Cedirian, Stephano;La Placa, Michelangelo;Piraccini, Bianca Maria;Raschi, Emanuel;Starace, Michela
2025

Abstract

The unique immunomodulatory properties of hydroxychloroquine (HCQ) have attracted considerable interest beyond its use for malaria and rheumatological diseases, including a variety of dermatological conditions. Over recent years, especially after the coronavirus disease 2019 (COVID-19) pandemic, the prescription of HCQ has also significantly expanded, sometimes inappropriately, thus posing additional challenges on its optimal use, due to emerging safety issues. In this review, we provide dermatologists with the latest advancements on selected clinically relevant toxicities, namely retinopathy, pro-arrhythmia, cutaneous reactions, and neuropsychiatric effects. It is hoped this update can assist dermatologists to identify high-risk patients for tailored monitoring, screening, and risk minimization strategies, thus supporting safer HCQ prescribing.
2025
Rapparini, L., Cedirian, S., La Placa, M., Piraccini, B.M., Raschi, E., Starace, M. (2025). Safety of Hydroxychloroquine: What a Dermatologist Should Know. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 26(2), 251-264 [10.1007/s40257-025-00919-x].
Rapparini, Luca; Cedirian, Stephano; La Placa, Michelangelo; Piraccini, Bianca Maria; Raschi, Emanuel; Starace, Michela
File in questo prodotto:
File Dimensione Formato  
40257_2025_Article_919.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale (CCBYNC)
Dimensione 893.95 kB
Formato Adobe PDF
893.95 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/1006827
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact